THE OBSERVATION by Pantelouris (1968) that nu/nu mice lack morphological and functional thymus glands opened up the possibility for the use of these animals in xenograft experiments. Rygaard & Povlsen (1969) were the first to grow heterotransplanted tumours in nude mice. Since then numerous experiments with xenografted human malignant tumours into thymus-deficient mice have been published from which it is evident that human tumour transplants in athymic mice can retain certain characteristics of the original tumour cell line (Pesce et al., 1977; Helson et al., 1975; Dipersio et al., 1980; Papsidero et al., 1981) . In this context it is of special interest to seek human tumours capable of producing carcinoembryonic antigen (CEA) when grafted into nude mice.
CEA is a tumour-associated glycoprotein discovered by Gold & Freedman (1965) which now has gained considerable interest as a tumour -marker in the management of patients with various tumours. There is general agreement that the amount of circulating CEA increases with increasing tumour mass and tumour extension (Lo Gerfo & Herter, 1975; Holyoke et at., 1975) . However, there are also cases with metastatic tumour growth but scarcely any circulating CEA. Moreover, unexplained fluctuations of the serum CEA concentrations are frequently detected in patients which can lead to severe misinterpretation of the clinical course of disease (Rittgers et al., 1978; Staab et at., 1979) .
Several investigators (Sordat et al., 1974; Miwa et at., 1976; Carrel et al., 1976; Stragand et al., 1980) have reported detection of CEA in the blood of nude mice after transplantation of colonic carcinomas into animals. While Miwa et al. (1976) 
RESULTS

Growth curves
The growth curves of HT 29 and SLu cells injected s.c. into the flanks of nude mice characterized by tumour volume and serum CEA concentration followed Gompertzian growth behaviour (Fig. 1) . The tumours grew locally and metastases were not observed. All sublines exhibited an apparent lag phase of tumour growth followed by a period of 17-36 days of logarithmic growth depending on the xenografted tumour cell subline. Thereafter, we observed decreasing growth rates generally followed by a plateau of tumour growth. The serum CEA concentration, concomitantly measured, matched exactly the growth characteristics of the cell lines, thus reflecting accurately the various phases of tumour growth. In corresponding pooled sera. The correlation coefficient between tumour mass and circulating CEA was found to be 0 977 (n = 14). Individual tumour masses of animals with HT 29-2 tumours, when correlated with the individual serum CEA concentrations, also showed a correlation with a coefficient of 0 820 (n= 31).
Since there was an excellent relationship between tumour volume and tumour mass for the HT 29 sublines (Fig. 2) we determined a volume/CEA relationship instead of a tumour mass/CEA relationship to economize on animals. During the logarithmic growth phase, tumour volumes of individual mice could be determined 2-3 times together with a corresponding blood sample. The results presented in Fig. 3a 29 and SLu sublines releasing different amounts of CEA into the host circulation. In this animal model the serum concentration of the human tumour marker, CEA, proved to be an excellent growth parameter directly correlated with tumour size. A critical examination of the various phases of tumour growth indicated that this strict correlation was upheld only in the logarithmic growth phase. The shift to slower growth rates was linked to the dissociation of serum CEA and tumour volume leading to lower levels of circulating CEA. The critical tumour mass of s.c.-growing tumours at which the shift to slower growth rates occurred was 800-1200 mg independent of the tumour cell sublines. These tumours frequently showed macroscopic necrosis. The length of logarithmic growth phases of s.c. growing tumours depended highly on the doubling times of the cell line and required 6-8 5 doubling times to reach the shift in the growth rate. The CEA output of HT 29 and SLu sublines in vivo reflected the CEA release of the cells in vitro. The sublines releasing high amounts of CEA in vitro also retained this characteristic in vivo, though we have to expect CEA catabolism in the mouse (Thomas & Hems, 1975) . The findings of Miwa et al. (1976) concerning the linear relation of tumour mass and circulating CEA have been confirmed and widely extended in our investigations. The conflicting results published by Stragand et al. (1980) , who did not find a correlation between tumour size and serum CEA levels with the LoVo adenocarcinoma cell line transplanted into nude mice, may come in part from evaluating animals with tumours at different growth phases. In a recent publication by Lewis & Keep (1981) no clear correlation between serum CEA levels and tumour size was reported. They used xenografted tumour tissue which developed central necrosis as a consistent feature when grown in nude mice.
Necrosis as an interfering event for the linear relation of a serum tumour marker and tumour size has been described for AFP-secreting human teratomas in immunosuppressed mice (Raghavan et al., 1980) . Our observations that fluctuations of the serum CEA concentration occurred only after the shift from logarithmic to slower growth rates, associated with the frequent appearance of macroscopic necrosis, might also reflect a direct interference of tumour necrosis with CEA release. Experiments to characterize a possible influence of tumour necrosis on CEA release are in progress.
